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ABSTRACT 
Objective: The present paper aims to evaluate the quality of five different brands (local and imported) of oral film-coated tablets of generic 
Amlodipine besylate 5 mg marketed in Sana`a-Yemen, through physiochemical parameters.  
Methods: Different physicochemical parameters, including the uniformity of tablet weight, hardness, thickness, disintegration time, and an assay of 
active ingredients, were conducted to validate the quality of generics Amlodipine Besylate 5 mg according to USP specification. 
Results: From the obtained results, it was observed that all the brands of Amlodipine Besylate 5 mg have passed the tests and met the specifications 
of USP. Results of weight variation, hardness, thickness, and disintegration time were ranged from-3.8 % to+5.13 % to-1.25 % to+3.25 %, 5.06±0.31 
to 13.21±1.5, 2.682±0.04 to 3.676±0.01 and 25 s to 2 min: 30 s, respectively. The dissolution test and the assay results of all the brands are also 
ranged within the acceptable label claim 93.7±2.24 to 98.4±0.85 and 93.22±0.38 to 100.15±0.33, respectively. However, there is no relation was 
found between the disintegration time and the dissolution test. 
Conclusion: According to the finding, all the selected Amlodipine Besylate 5 mg brands are met pharmacopeia standards and USP specifications. 
Therefore, the local and imported Amlodipine Besylate 5 mg can be used safely to get the desired therapeutic efficiency.  
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INTRODUCTION 
Over the past several decades, the term hypertension has been 
widely used in most of medical cases. Hypertension (also known as 
high blood pressure) is the potential risk factor for A) 
cardiovascular, such as congestive heart failure, myocardial 
infarction, stroke, ruptured aortic aneurysm, and B) renal disease [1, 
2]. Many factors can be attributed to the risk of hypertension, such 
as high sodium intake, unhealthy diet habits, stress, poor physical 
activity, and alcohol composition [3, 4]. Katherine T Mills et al. had 
reported that 31.1 % of adults had high blood pressure as the 
highest percentage was found in the low-and mild-income countries 
(31.5%) while the high-income countries showed low percentage 
(28.5%) [3, 5]. However, many pharmaceutical companies started to 
manufacture different types of medicine to control the high blood 
pressure and the adversities for these pharmaceutical products 
through printed bills, electronic media and newspapers. These 
products may be i) branded (original and proved by FDA), ii) 
unbranded (generics called a faithful imitation of a mature drug but 
not approved by a patent, had the same active ingredients and 
expected to show bio-equivalent to the branded drug) and iii) 
sometimes, fake [6]. Hence, quality control investigations are an 
important strategy to access the medicines as interchangeable drugs 
before distributing them to the population, especially in low-income 
countries and cities under conflicts or war. 
Amlodipine was patented by Pfizer under the brand name Norvasc. 
Amlodipine, a third-generation dihydropyridine, is a long-acting L-
calcium channel blocker used worldwide, in the treatment of 
hypertension and angina pectoris. It decreases blood pressure by 
the relaxation of vascular smooth muscles and vascular dilatation 
mechanism [7]. After the expiration of the Amlodipine patent in 
2007, several of generic versions became available [8]. The chemical 
name of Amlodipine is 3-ethyl 5-methyl 2-[(2-aminoethoxy) 
methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-
dicarboxylate and its structure is represented in fig. 1. Amlodipine is 
considered a moderate drug release [9] and is available in three 
strength forms: 2.5, 5, and 10 mg. 
 
Fig. 1: The chemical structure of Amlodipine 
 
To improve the solubility and enhance the bioavailability of the 
Amlodipine, different formulations of Amlodipine conjugated salts 
have been generated and commercially available. Some of these 
forms are: Adipate [10], Nicotinate [11], and Besylate [12, 13]. On 
the other hand, combination drugs are used to increase the 
effectiveness of the hypertension medication along with decreasing 
the undesired effects are also reported [14-16]. In 2010, sheikh et al. 
developed a tablet formulation of S-(-)-Amlodipine Besylate chiral 
separation drug and Nebivolol Hydrochloride for better 
management of hypertension [17]. In 2012, Sukhavasi et al. 
published a formulation of amlodipine besylate tablets with 
Fenugreek seed mucilage and Ocimum basilicum gum [18]. These 
generics should be demonstrated to in vitro and in vivo quality 
control studies before being established in the markets. However, 
Amlodipine’s biowaiver conditions are considered as a candidate for 
a biowaiver through dissolution testing [19-21].  
Medicines may undergo a potential change during storage due to 
temperature or humidity. What’s more, surveillance for local 
pharmaceutical factories and conflicts may also be affected on the 
drug quality. On the other hand, the third goal, which is reported 
in Sustainable Development Goals is good health and well-being; 
hence, it’s important to confirm the quality of medicines before 
distributed to the markets. The presence research aims to analyze 
five different generic products of oral film-coated tablets of 
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Amlodipine Besylate tablets 5 mg that are commercially available 
in Yemeni markets. Two of these are locally manufactured by 
Yemen pharmaceutical factories, whereas, three Amlodipine 
tablets are imported from Germany, Hungary, and Egypt. The 
investigation is devoted to in vitro various physiochemical studies 
of Amlodipine tablets 5 mg through different quality control 
parameters such as thickness, hardness, disintegration test, 
dissolution time, and drug content. A comparison was carried out 
in vitro drug release test with chemical content between all 
selected brands. 
MATERIALS AND METHODS 
Study area and period 
The study was conducted from February to June 2021 at Saba 
Pharma Pharmaceutical Plant, which is located in Sana’a city, 
Republic of Yemen.  
Techniques 
Analytical balance (model: GR-120, AND Weighing, Japan), 
disintegration tester (ED-2L, Electrolab, India), HPLC (Binary, Jasco, 
Japan), tablet hardness tester (DH250, THERMONIK, India), 
dissolution test apparatus (DT-810, Jasco, Japan), pH meter (3520, 
Jenway, United Kingdom), UV-VIS spectrophotometer (V-730, Jasco, 
Japan) and ultrasonic cleaner (CSA-10BT, Sapeen, Shanghai).  
Reagent 
Standard Amlodipine was purchased from Merck (USA). Methanol, 
hydrochloric acid, acetonitrile, phosphoric acid and triethylamine were 
purchased from SDFCL (India) and used without further purification. 
Sample collection 
Table 1 is illustrated the label information of five selected brands of 
Amlodipine Besylate 5 mg tablets that sold in Yemeni Market.
  
Table 1: Label information (Country, manufacturing date, expiry date and batch No.) of Amlodipine Besylate 5 mg tablets A-E 
Brand code Country Manufacturing date Expiry date Batch No. 
A Germany June/2020 June/2022 9uk24849 
B Hungary September/2019 September/2022 T99630A 
C Egypt April/2019 April/2023 19104067 
D Yemen March/2020 March/2022 20288A 
E Yemen December/2019 December/2022 19353 
 
Methods  
United States Pharmacopoeia procedures were used to identify the 
quality of coated film Amlodipine tablets [22].  
Weight variation test  
Twenty tablets were randomly picked from each brand and 
individually weighed by using the electronic balance. The average 
weight of the tablets was calculated and compared with the individual 
weights. The weight deviation and the percentage deviation of each 
tablet were calculated based on Formulas 1 and 2, respectively.  
Weight deviation = average weight
× permissible percentage deviation. (1) 
% deviation for each tablet =  
(Wttab)  −  (Wtavg)
(Wtavg) 
 × 100 … . (2) 
Where: Wtavg = Average weight of tablets, Wttab = Individual 
weight of each tablet. 
Table 2 illustrates the maximum % difference allowance for tablet 
weight variation as reports in The United States Pharmacopoeia 
(USP). 
 
Table 2: The accepted percentage weight deviation for the 
tablets 
Average weight of tablets (mg) Maximum % difference allowed 
130 or less 10 % 
130 to 324 7.5 % 
More than 324 5 % 
 
Hardness test 
Ten tablets were selected randomly from each brand. A tablet 
hardness tester was utilized for this test and the hardness of each 
tablet was calculated automatically by measuring the required 
pressure to break the tablet. The mean hardness and±standard 
deviation (SD) were calculated. 
Thickness 
Ten tablets from each brand were taken randomly and the thickness 
was determined in micrometers. 
Disintegration test 
Six tablets from each brand were placed in an individual tube and 
covered by disc. Disintegration USP II puddle tester was performed. 
Water was added as a disintegration media and the temperature was 
maintained at temperature 37±2 °C as the apparatus was operated. 
The assembly was raised and lowered between 29 and 32 cycles per 
minute. When all the masses were entirely dissolved, the time was 
recorded by second (s) esteem to complete the disintegration test.  
Dissolution test 
The dissolution test was performed by using dissolution tester USP 
apparatus-II (paddle) at the rotation speed of 75 revolution per minute 
(rpm). The dissolution medium was a buffer solution (0.01 N 
hydrochloric acid, pH 6.8) and the temperature was kept at 37±0.5 °C. 
The tablets were immersed in the dissolution media (500 ml) for 30 min 
(min). Subsequently, the solution was filtered to remove the insoluble 
solids. Two ml of the filtrated solution was taken and diluted with a 
buffer solution (98 ml) to make the final volume of 100 ml. Finally, the 
solution was assayed by Uv-Vis spectrophotometer at λmax 239 nm and 
the absorbance was recorded. The hydrochloric acid buffer solution was 
used as a blank. To determine the percentage of drug release, the 
obtained absorbance was compared with the standard solution 
absorbance and the drug release % was calculated using Formula 3: 
Absorbance of the test solution ×  Concentration of the standard solution
Absorbance of the standard solution × Concentration of the test solution  
× 100 … (3) 
Assay test 
The drug content assay was performed according to the procedure 
that is presented in United States Pharmacopoeia. Ten tablets of 
Amlodipine Besylate were finely powdered and weighed 
equivalently to the average weighted tablets. To prepare the buffer 
solution, 7 ml of trimethylamine was placed into a 1000 ml 
volumetric flask and complete the volume with water. Adjust the pH 
to 3 by the addition of phosphoric acid (1 N). The Amlodipine 
powder was transferred to a 50 ml volumetric flask followed by the 
addition of 40 ml of mobile phase (Mobile phase was Acetonitrile: 
Methanol: Buffer solution at the ratio 1.5:3.5:50, respectively). After 
that, the mixture was subjected to sonication for 10 min, cooled, and 
the volume was made up to 50 ml by the addition of the mobile 
phase. Then, the mixture was filtered through 0.45 mm pore size to 
remove the insoluble materials and the first 3 ml of filtrate was 
discarded. 5 ml of the clear solution was transferred into 100 ml 
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volumetric flask and diluted with the mobile phase to volume 
(concentration = 0.05 g/l). Finally, 50 µl of the sample was injected 
in High-performance liquid chromatography (HPLC) with the flow 
rates 1 ml/min. The UV-visible spectrophotometer detector was set 
at 237 nm. The standard solution was tested three runs by using UV-
vis spectrophotometer and the average was calculated. On the other 
hand, three replicate injections of Amlodipine samples were injected 
and the % of drug content was assessed by using Formula 4.  
Area of the test solution ×  Concentration of the standard solution
Area of the standard solution ×  Concentration of the test solution 
 
× 100 … (4) 
RESULTS AND DISCUSSION  
The results of physicochemical properties including weight 
variation, hardness, thickness and disintegration test, % drug 
release along with % drug content of the selected Amlodipine 5 mg 
tablets brands A-E are tabulated in tables 3 and 4, respectively.  
Weight variation test  
The weight variation test (uniformity of weight) gives information 
about the manufacturing quality, applicable tablets particle size, and 
the content uniformity of the drug formulation [23]. In terms of 
average weight, all the studied brands did not deviate from USP 
specification (±7.5 %). It ranged from-3.8 % to+5.13 % to-1.25 % 
to+3.25 % (table 3). However, small % SD values are a sign of the 
high homogeneity of the active ingredient and weight distribution of 
the Amlodipine tablets, and hence, it provides the desired 
therapeutic response [24].  
Hardness test 
The hardness test measures the capability of the tablet to resist 
mechanical shock in handling, manufacturing, packaging, and 
shipping [25]. The hardness of five brands of Amlodipine was 
calculated and found as: 10.59±0.97, 13.21±1.5, 6.68±0.66, 
5.06±0.31 and 9.26±1.77 for brands A, B, C, D and E, respectively 
(table 3). All the hardness results met the USP specification.  
Thickness test 
The thickness test provides information about the variation between 
tablets. However, it should be controlled within a±5 % variation of a 
standard value. According to table 3, the average thickness was 
ranged between 2.682±0.04 (brand D) to 3.676±0.01 (brand A). 
  
Table 3: Physicochemical results weight variation, hardness, thickness of brands A-E 
Brand Weight deviation %   Hardnessa,b   Thicknessa,b(mm) 
A -1.25 % to+3.25 % 10.59±0.97 3.676±0.01 
B  -1.28 % to+2.23 %  13.21±1.5 3.277±0.02 
C -2.08 % to+2.2 % 6.68±0.66 2.887±0.02 
D  -1.5 % to+2.03 % 5.06±0.31 2.682±0.04 
E  -3.8 % to+5.13 % 9.26±1.77 3.027±0.09 
aThe results aremean±SD (SD: Standard Deviation), bNumber of replicated = 10  
 
Disintegration time 
Drug release rates can be controlled by the amount of polymers used 
for surface coating [26]. The disintegration times were determined 
for all five brands and the results are shown in table 4. Brands A, B, C 
and E disintegrated in 25 s, 35 s, 41 s, 55 s, respectively, while brand 
D disintegrated in 2 min: 30 s. Even though all brands are in good 
agreement with the USP specification (disintegration time should be 
less than 15 min), there is a significant variation in the results. This 
variation can be explained in terms of drug formulation (type and 
quantity of disintegrants). Sodium starch glycolate entity, binders, 
microcrystalline cellulose, and lubricants that exist in the drug 
formulations fastens the disintegration, and hence, improves the 
drug stability [27-29].  
Dissolution test 
The dissolution test (drug release) is an important test in quality 
parameters because it reflects the absorption and bioavailability of 
the drug. It might be affected by the disintegration test [28-31]. 
According to USP, 75 % of the drug (Q) should be dissolved within 
30 min. This value corresponds to gastric emptying half-life (T50%) 
in fasting conditions [30]. Drugs with poor dissolution profiles will 
decrease the bioavailability of the drug, thereby leading to 
therapeutic failure [31, 32]. After 30 min, the drug release of 
selected Amlodipine brands ranged from 93.7±2.24 % to 98.4±0.85 
%. Brand D (98.4±0.85) and brand B (98.3±1.06) showed the highest 
percentage of drug release of the entire samples. From table 4, it is 
observed that there is no relation between the disintegration and in 
vitro drug release. Various attempts have been developed to 
improve the quality of the dissolution and hence bioavailability of 
drugs [33], enteric coating is one of the strategies performed alone 
or in combination with other approaches [34, 35]. 
Assay test 
The content uniformity test (assay test) implements to confirm that 
all tablets contained the active ingredient content of the desired 
drug [36]. The USP provides the monograph for the determination of 
Amlodipine in the film-coated tablet using HPLC with an ultraviolet 
detector. The accepted limit for Amlodipine Besylate is 90 %-110 % 
with the standard deviation less or equal to 6 %. Table 4 revealed 
the satisfied contents of the active ingredient as 100.15±0.33, 
97.46±0.35, 99.21±0.17, 98,36±0.79 and 93.22±0.38 for brands A, B, 
C, D and E, respectively. Brand A has the highest content of 100.15 
%, whereas brand E shows the lowest content of 93.22 %. Despite 
the varsity of the drug content among the brand, but values are still 
in good agreement with the pharmacopeial requirements. 
 
Table 4: Disintegration test, % drug release and % drug content results of brands A-E 
 Brand Disintegration time  % Drug releasea,b % Drug contenta,c 
A 25 s 93.7±2.24 100.15±0.33 
B 35 s 98.3±1.06 97.46±0.35 
C 41 s 96.7±0.80 99.21±0.17 
D 2:30 min. 98.4±0.85 98.36±0.79 
E 55 s 97.9±4.9 93.22±0.38 
aThe results aremean±SD (SD: Standard Deviation), bNumber of replicated = 6, cNumber of replicated = 3  
  
CONCLUSION  
Several quality control parameters, including weight variation, 
hardness, thickness, disintegration time, dissolution and assay tests, 
were conducted to evaluate the quality of five different Amlodipine 5 
mg brands that are available in pharmaceutical markets in Yemen. 
The investigation revealed that the five brands of Amlodipine 5 mg 
tablets complied with pharmacopoeial limits (USP). No significant 
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differences were observed in weight variation and thickness. The 
disintegration time was ranged from 25 s (brand A) to 2:30 (brand 
D). The dissolution test of all brands was found between 93.7±2.24 
and 98.4±0.85%. In this study, the disintegration time did not show 
a direct relationship with their drug release. The assay results 
revealed the drug content of the brand was ranged from 93.22±0.38 
% to 100.15±0.33 %. In conclusion, the selected local and imported 
Amlodipine Besylate 5 mg generics are pharmaceutical equivalence 
and met the quality limit according to USP specifications; therefore, 
the local Amlodipine Besylate 5 mg can be used safely to get the 
desired therapeutic efficiency.  
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